Conclusions
- HR mutations present in 13.0% of tumors
- Most commonly mutated lineages include ovarian (14.1%), bladder (9.7%), breast (8.0%), endometrial (7.4%), prostate (7.1%), and pancreas (6.5%)
- Most commonly mutated HR genes include PTEN (5.8%), BRCA2 (2.8%), BRCA1 (2.6%), and ATM (1.2%)
- BRCA1/2 mutations significant among female malignancies and CRC
- PALB2 mutations appreciated in 2.7% of bladder tumors; also seen in pancreatic cancer, NSCLC, CRC